FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today reported financial results for Laboratory Services MSO, LLC (“LSM”) for the twelve months ended December 31, 2022. In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.
LSM 2022 Financial Highlights
“We are pleased to report strong financial results and profitability for LSM in 2022, which we believe is further validation of our strategic investment,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “LSM offers an extensive test menu, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, with quick turnaround times. Our goal is to continue to grow LSM’s top and bottom line by taking advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with exceptional performance, a positive revenue track record and niche-market advantage, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies.”
Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
This email address is being protected from spambots. You need JavaScript enabled to view it.
(tables follow)
| LABORATORY SERVICES MSO, LLC AND AFFILIATES | ||||||
| COMBINED BALANCE SHEETS | ||||||
| December 31, | ||||||
| 2022 | 2021 | |||||
| ASSETS | ||||||
| CURRENT ASSETS: | ||||||
| Cash | $ | 439,778 | $ | 607,982 | ||
| Accounts receivable | 4,088,069 | 3,086,966 | ||||
| Other current assets | 86,277 | - | ||||
| Total Current Assets | 4,614,124 | 3,694,948 | ||||
| NON-CURRENT ASSETS: | ||||||
| Operating lease right-of-use assets, net | 1,758,063 | - | ||||
| Finance lease right-of-use assets, net | 291,419 | - | ||||
| Property and equipment, net | 14,667 | 18,667 | ||||
| Total Non-current Assets | 2,064,149 | 18,667 | ||||
| Total Assets | $ | 6,678,273 | $ | 3,713,615 | ||
| LIABILITIES AND MEMBER'S EQUITY | ||||||
| CURRENT LIABILITIES: | ||||||
| Accounts payable | $ | 573,395 | $ | 184,139 | ||
| Accrued payroll liability | 38,589 | 42,077 | ||||
| Operating lease obligation | 229,874 | - | ||||
| Finance lease obligation | 112,457 | - | ||||
| Total Current Liabilities | 954,315 | 226,216 | ||||
| NON-CURRENT LIABILITIES: | ||||||
| Operating lease obligation - noncurrent portion | 1,680,017 | - | ||||
| Finance lease obligation - noncurrent portion | 178,962 | - | ||||
| Total Non-current Liabilities | 1,858,979 | - | ||||
| Total Liabilities | 2,813,294 | 226,216 | ||||
| Commitments and Contingencies | ||||||
| MEMBER'S EQUITY | 3,864,979 | 3,487,399 | ||||
| Total Liabilities and Member's Equity | $ | 6,678,273 | $ | 3,713,615 | ||
| LABORATORY SERVICES MSO, LLC AND AFFILIATES | ||||||
| COMBINED STATEMENTS OF INCOME | ||||||
| For the Year Ended | For the Year Ended | |||||
| December 31, 2022 | December 31, 2021 | |||||
| REVENUE | $ | 14,689,747 | $ | 18,278,430 | ||
| COST OF REVENUE | 6,612,268 | 5,002,674 | ||||
| GROSS PROFIT | 8,077,479 | 13,275,756 | ||||
| OPERATING EXPENSES: | ||||||
| Selling and marketing expense | 1,344,552 | 480,269 | ||||
| Professional fees | 714,662 | 375,667 | ||||
| Other general and administrative expenses | 296,704 | 281,128 | ||||
| Total Operating Expenses | 2,355,918 | 1,137,064 | ||||
| OPERATING INCOME | 5,721,561 | 12,138,692 | ||||
| OTHER INCOME (EXPENSE) | ||||||
| Forgiveness of Paycheck Protection Program loan | - | 95,000 | ||||
| Employee Retention Tax Credit | 609,634 | - | ||||
| Other income | 11,938 | 24,330 | ||||
| Total Other Income, net | 621,572 | 119,330 | ||||
| INCOME BEFORE INCOME TAXES | 6,343,133 | 12,258,022 | ||||
| INCOME TAXES | - | - | ||||
| NET INCOME | $ | 6,343,133 | $ | 12,258,022 | ||
| Last Trade: | US$2.71 |
| Daily Change: | -0.07 -2.52 |
| Daily Volume: | 20,807 |
| Market Cap: | US$43.310M |
August 14, 2024 July 31, 2024 July 18, 2024 April 22, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
